Methylene blue
Established medicineAlso known as Atrosept, Azul de metileno, Basic Blue 9, C.I. basic blue 9+50 more
Atrosept, Azul de metileno, Basic Blue 9, C.I. basic blue 9, Chlorure de méthylthioninium, Cloruro de metiltioninio, Cystemms-V, Darcalma, Darpaz, Dolsed, Hyolev MB, Hyophen, Lowacryl blue 9, MHP-A, MSP-Blu, Methylene blue stain, Methylenium ceruleum, Methylthioninii chloridum, Phosphasal, Prosed DS, Provayblue, Solvent blue 8, Swiss blue, Trac Tabs 2x, UAA, UTICAP, Uramit MB, Urapine, Urelle, Uretron, Uretron DS, Uri-Sep SC, Uribel, Uribel Tabs, Uridon Modified, Urimar Reformulated Oct 2013, Urimar T, Urimax, Urin DS, Urised, Uritin, Uro-Blue, Urogesic Blue Reformulated Apr 2012, Urogesic-Blue, Urolene Blue, Urolet MB, Usept, Ustell, Utira, Utrona-C, Methylthioninium chloride, Methylthioninium chloride stain, Prosed/DS, Urin D/S.
Recent clinical, regulatory, research and industry developments relating to this drug.
Tailored novel nanocomposites for advanced elimination of methylene blue dye from water
Adjunctive Methylene BLUe in Septic SHock: a Pilot Randomized Controlled Trial
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials